Cellular HIV-1 immune responses in natural infection and after genetic immunization

Scandinavian Journal of Infectious Diseases

Volumn 33, Issue 2, 2001, Pages 83-96

  Calarota, S A ^a   Wahren, B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CYTOKINE; DNA; DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEF PROTEIN; REV PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG SAFETY; GENE DELETION; GENE MUTATION; GENETIC TRANSFECTION; HELPER CELL; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; INFECTION RESISTANCE; INFECTION RISK; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MEMORY CELL; METHODOLOGY; MOLECULAR RECOGNITION; NONHUMAN; REVIEW; T LYMPHOCYTE; VIRUS LATENCY; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

AIDS VACCINES; ANIMALS; CLINICAL TRIALS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; MODELS, ANIMAL; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 0035116251     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655401750065445     Document Type: Review

References (168)

1. Virus-specific CD8 + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
2. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
3. CD8 + T cells suppress human immunodeficiency virus replication by inhibiting viral transcription
4. Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication
5. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
6. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
7. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS
8. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors
9. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression
10. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients
11. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients
12. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells
13. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome
14. DNA increases the potency of vaccination against infectious diseases
15. Genetic immunization: A new era in vaccines and immune therapeutics
16. Gene inoculation generates immune responses against human immunodeficiency virus type 1
17. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine
18. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys
19. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
20. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
21. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
22. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial
23. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
24. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses
25. HIV-specific cytotoxic T lymphocytes in seropositive individuals
26. AIDS virus-specific cytotoxic T lymphocytes in lung disorders
27. Cytotoxic T lymphocytes against HIV
28. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans
29. Carboxyl-terminal and central regions of human immunodeficiency virus-1 nef recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis
30. Detection of a vigorous HIV-1-specific cytotoxic T lymphocyte response in cerebrospinal fluid from infected persons with AIDS dementia complex
31. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes
32. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women
33. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8 + lymphocyte activity
34. Cytotoxic T lymphocyte epitopes: Implications for HIV vaccines
35. Different patterns of HIV-1-specific cytotoxic T-lymphocyte activity after primary infection
36. Cytotoxic T lymphocytes in human immunodeficiency virus infection: Regulator genes
37. A CD4 + cytotoxic T-lymphocyte clone to a conserved epitope on human immunodeficiency virus type 1 p24: Cytotoxic activity and secretion of interleukin-2 and interleukin-6
38. Human CD4 + cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine
39. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: In vitro quantification of effector cell populations with p17 and p24 specificities
40. Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins
41. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease
42. Human immunodeficiency virus type 1 (HIV-1)- and Epstein-Barr virus-specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1 infected persons
43. CD8 + lymphocytes can control HIV infection in vitro by suppressing virus replication
44. Controlling HIV pathogenesis: The role of the noncytotoxic anti-HIV response of CD8 + T cells
45. CD8 + cell-derived anti-human immunodeficiency virus inhibitory factor
46. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8 + T cells
47. HIV suppression by interleukin-16
48. Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection
49. Evolution and plasticity of CTL responses against HIV
50. An activated CD8 + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status
51. HIV-1-specific cytotoxic T lymphocyte responses in the first year of life
52. Role of cellular immunity in protection against HIV infection
53. Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8 + T cells: Cytotoxic T-lymphocyte epitopes and precursor frequencies
54. A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes
55. Human immunodeficiency virus pseudotypes with expanded cellular and species tropism
56. Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses
57. Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model
58. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals
59. Rapid effector function in CD8 + memory T cell
60. Counting antigen-specific CD8 T cells: A re-evaluation of bystander activation during viral infection
61. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry
62. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
63. Immune responses in HIV-exposed seronegatives: Have they repelled the virus?
64. Protective immunity against HIV infection: Has nature done the experiment for us?
65. Immune correlates of protection from HIV and AIDS - More answers but yet more questions
66. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons
67. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: Evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects
68. Viral mutations, TCR antagonism and escape from the immune response
69. Effects of HIV-1 Tat on expression of HLA class I molecules
70. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein
71. Virus escape from CTL recognition
72. T cell responses and viral escape
73. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 Nef protein
74. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 gag variants
75. Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants
76. Cytotoxic T lymphocytes in HIV-1 infection: A killing paradox?
77. Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection
78. Early T-helper cell defects in HIV infection
79. Characteristics of the specific cell-mediated immune responses in human immunodeficiency virus infection
80. HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals
81. HIV type 1-specific helper T cells: A critical host defense
82. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection
83. Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: Relationship to cellular immune responses
84. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160
85. Induction of specific T-cell responses in HIV infection
86. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: A randomised double-blind placebo-controlled trial
87. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: Evaluation of the T cell proliferative response
88. Gene vaccination: Plasmid DNA is more than just a blueprint
89. DNA vaccines: Protective immunizations by parenteral, mucosal, and gen-gun inoculations
90. Heterologous protection against influenza by injection of DNA encoding a viral protein
91. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
92. Genetic immunization is a simple method for eliciting an immune response
93. Influenza virus nucleoprotein-specific immunoglubulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery
94. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization
95. Induction of HIV-1 specific mucosal immune responses by DNA vaccination
96. Plasmid DNA vaccination: Mechanism of antigen presentation
97. Nucleic acid vaccines: An overview
98. Priming of cytotoxic T lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes
99. DNA vaccines: Mechanisms for generation of immune responses
100. In vivo priming by DNA injection occurs predominantly by antigen transfer
101. Immune responses to the HIV rev regulatory gene
102. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains
103. The human immunodeficiency virus type 1 Rev protein shuttles between the cytoplasms and nuclear compartments
104. HIV accessory proteins as therapeutic targets
105. Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation
106. Expression of HIV regulatory DNA vaccine constructs
107. Nucleic acid vaccination with HIV regulatory genes: A combination of HIV-1 genes in separate plasmids induces strong immune responses
108. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease
109. Structure and expression of tat-, rev-, and nef-specific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and macrophages
110. Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo
111. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
112. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects
113. Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease
114. Long-lasting recovery in CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
115. Quantification of HIV-1-specific cytotoxic T lymphocytes and plasma viral load of viral RNA
116. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
117. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy
118. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
119. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection
120. Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy
121. Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection
122. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
123. CpG motifs in bacterial DNA trigger direct B-cell activation
124. CpG motifs as immune adjuvants
125. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
126. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
127. Potential DNA vaccine integration into host cell genome
128. Plasmid DNA malaria vaccine: The potential for genomic integration after intramuscular injection
129. Novel vaccine approaches
130. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I Env/Rev vaccine in HIV-infected recipients: Follow-up data
131. Multiple injections of plasmid encoding HIV-1 reverse transcriptase induce antibodies against double-stranded DNA
132. Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1
133. Cell-mediated suppression of HIV-specific cytotoxic T lymphocytes
134. A lectin-binding soluble factor released by CD8 + CD57 + lymphocytes from AIDS patients inhibits T cell cytotoxicity
135. Cross-clade T cell recognition of HIV-1
136. Modulation of HIV immune responses in natural infection and after genetic immunization [dissertation]
137. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8 + cytotoxic activity after receipt of envelope vaccines
138. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccines
139. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
140. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160
141. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
142. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1 MN gp120, HIV-1 SF2 recombinant gp120, or both vaccines in seronegative adults
143. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
144. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS)
145. A Th1 → Th2 switch is a critical step in the etiology of HIV infection
146. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood
147. Mapping of IgG subclass and T-cell epitopes on HIV proteins by synthetic peptides
148. HIV-1 peptides induce a proliferative response in lymphocytes from infected persons
149. Cellular and humoral antigenic epitopes in HIV and SIV
150. CD4+ T cell epitopes in HIV-1 proteins
151. A dose-ranging study of a prototype synthetic HIV-1 MN V3 branched peptide vaccine
152. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection
153. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120. A randomized, double-blind trial
154. HIV-1 MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1 MN recombinant glycoprotein 120 vaccine
155. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI)
156. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial
157. Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages
158. Anti-HIV-1 ADCC
159. Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection
160. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects
161. Analyses of functional antibody responses in HIV-1-infected individuals after vaccination with rgp160
162. Systematic identification of optimal HIV-1 CTL epitopes
163. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes
164. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens
165. Cytotoxic CD8 + T lymphocytes reactive with human immunodeficiency virus-1 produce granulocyte/macrophage colony-stimulating factor and variable amounts of interleukins 2, 3, and 4 following stimulation with the cognate epitope
166. T-cell-mediated immunopathology versus direct cytolysis by virus: Implications for HIV and AIDS
167. Induction of HIV-1 replication in a chronically infected T-cell line by cytotoxic T lymphocytes